Antonio Calles
Madrid, MD 28007, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Real-World Insights into Stage I-III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study.
Journal: Life (Basel, Switzerland)
Published: May 18, 2026
Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 23, 2026
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 20, 2026
Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testing.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: January 19, 2026
Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation Analysis.
Journal: Targeted oncology
Published: September 22, 2025
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
Journal: Nature cancer
Published: August 13, 2025
PD-L1 expression scoring using artificial intelligence algorithms in non-small cell lung cancer harbouring ROS1 fusions: potential clinical-biological significance.
Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: May 08, 2025
Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Journal: Cancer medicine
Published: February 27, 2025
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 21, 2024
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 22, 2024
Last Updated: 09/26/2026